Dublin-based healthtech startup Integumen has acquired RinoCloud, a Cambridge-based data management startup founded in 2015, for €3.5 million.
Integumen’s Labskin platform allows skin-care, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin.
Labskin AI is a laboratory-grown human-skin testing platform that completely eliminates the need for animal testing for the development of skin care products. The AI platform and physical Labskin laboratories offer clients an online end-to-end skin care product validation system, tested on laboratory grown human skin. Specifically developed to host harmful bacteria on simulated human skin, it’s perfect for antimicrobial products, such as anti-dandruff shampoos and anti-acne creams, anti-aging, anti-fungal, UV sun exposure, toxic shock, and drug delivery through the skin, which can’t be carried out in animal models due to the ethical constraints of testing harmful bacteria.
RinoCloud’s technology will provide Labskin clients with access to an AI machine learning platform which will enable them to accelerate the development of cosmetics, skincare, woundcare, personal hygiene and pharmaceutical topical drug delivery products – all without animal testing. The integrated service is expected to go live in Q4 2018.
“The RinoLab Team has developed a range of algorithms for the dissimination of big data specifically from scientific sources and is perfectly suited to analysing Labskin data to unlock trends and patterns that would normally be missed on a manual review,” said Fin Murray, CEO of RinoCloud. “Using RinoLab, Labskin AI clients are provided with suggested alterations to improve product formulations to increase efficiency and efficacy. RinoLab analysis provides supporting data for the ‘Product Information File’ required by cosmetic brand and skin care companies, prior to product launches in the US and EU markets.”